H.R. 5020: Synthetic Drug Awareness Act of 2016

To require the Surgeon General of the Public Health Service to submit to Congress a report on the effects on public health of the increased rate of use of synthetic drugs.

The bill’s titles are written by its sponsor.

What you can do



Apr 21, 2016


Referred to Committee on Apr 21, 2016

This bill was assigned to a congressional committee on April 21, 2016, which will consider it before possibly sending it on to the House or Senate as a whole.


Hakeem Jeffries

Representative for New York's 8th congressional district



Read Text »
Last Updated: Apr 21, 2016
Length: 2 pages


1% chance of being enacted according to PredictGov (details)


Apr 21, 2016

This is the first step in the legislative process.

Reported by Committee

Passed House

Passed Senate

Signed by the President

H.R. 5020 is a bill in the United States Congress.

A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

How to cite this information.

We recommend the following MLA-formatted citation when using the information you see here in academic work:

“H.R. 5020 — 114th Congress: Synthetic Drug Awareness Act of 2016.” www.GovTrack.us. 2016. October 28, 2016 <https://www.govtrack.us/congress/bills/114/hr5020>

Where is this information from?

GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.